Zhou Jingxiang, Xue Jiangdong, Wang Qiuju, Zhu Xia, Li Xingwei, Lv Wenliang, Zhang Dongming
College of Animal Science and Technology, Key Laboratory of Animal Production and Safety of Ministry of Education, Jilin Agricultural University, Changchun, 130118, China.
In Vitro Cell Dev Biol Anim. 2014 Jun;50(6):489-95. doi: 10.1007/s11626-014-9737-2. Epub 2014 Mar 12.
In order to construct the recombinant plasmid of pIRES-ORF81, the nucleic acid isolated from Koi herpes virus-CJ (KHV-CJ) strains was used as a template to insert the ORF81 gene fragments amplified by PCR into the pIRES-neo, a kind of eukaryotic expression vector. Using Western blotting analysis, it was verified that ORF81 gene protein can be expressed correctly by pIRES-ORF81, after MFC cells were transfected. The recombinant plasmid pIRES-ORF81 was set into three immunization dose gradients: 1, 10, and 50 μg/carp. Empty plasmid group, PBS group, and blank control group were set simultaneously. Giving intramuscular injections to healthy carps with an average body mass of 246 ± 20 g, indirect ELISA was used to regularly determine antibody levels after three times immunization injection. Neutralizing antibodies were detected by neutralization assay. The results of inoculation tests showed that the pIRES-ORF81 recombinant plasmid can induce the production of carp-specific antibodies. The differences of immune effect between the three different doses of immune gradients were not significant (P > 0.05), but they can induce the production of neutralizing antibodies. After 25 d of inoculation, carp mortality of pIRES-neo empty vector treatment groups was 85%, while the carp mortality of eukaryotic expression recombinant plasmid pIRES-ORF81 injected with three different doses of immune gradients was 20, 17.5, and 12.5%, respectively. Differences in comparison to the control group were highly significant (P < 0.01). However, histopathological section of immunohistochemistry organization revealed no significant changes. It demonstrated that the DNA vaccine pIRES-ORF81 constructed in the experiment displayed a good protective effect against KHV, which had the potential to industrial applications.
为构建pIRES-ORF81重组质粒,以从锦鲤疱疹病毒CJ(KHV-CJ)毒株中分离的核酸为模板,将通过PCR扩增得到的ORF81基因片段插入真核表达载体pIRES-neo中。经蛋白质免疫印迹分析验证,转染MFC细胞后,pIRES-ORF81可正确表达ORF81基因蛋白。将重组质粒pIRES-ORF81设置为三个免疫剂量梯度:1、10和50μg/尾鲤鱼。同时设置空质粒组、PBS组和空白对照组。对平均体重为246±20g的健康鲤鱼进行肌肉注射,三次免疫注射后定期用间接ELISA法测定抗体水平。通过中和试验检测中和抗体。接种试验结果表明,pIRES-ORF81重组质粒可诱导鲤鱼产生特异性抗体。三种不同剂量免疫梯度的免疫效果差异不显著(P>0.05),但均可诱导产生中和抗体。接种25d后,pIRES-neo空载体处理组鲤鱼死亡率为85%,而注射三种不同剂量免疫梯度的真核表达重组质粒pIRES-ORF81的鲤鱼死亡率分别为20%、17.5%和12.5%。与对照组相比差异极显著(P<0.01)。然而,免疫组织化学组织病理切片显示无明显变化。结果表明,本实验构建的DNA疫苗pIRES-ORF81对KHV具有良好的保护作用,具有潜在的工业应用价值。